Blood stem cell mutations accelerate biological aging
Your blood cells may be biologically older than your calendar age. New research links a common age-related mutation pattern in blood stem cells to measurably faster biological aging.
Inside bone marrow, stem cells continuously produce new blood cells. Sometimes one of these stem cells acquires a DNA error and begins to outcompete its neighbours. This process is called clonal hematopoiesis of indeterminate potential, or CHIP. It is not a disease, but an age-related phenomenon that becomes increasingly common after age sixty.
What makes CHIP particularly relevant for longevity research is its connection to epigenetic aging. The researchers conducted a systematic review and meta-analysis of five studies involving 7,483 individuals aged 55 to 79. They focused on epigenetic age acceleration (EAA), a measure of how much older a person’s DNA methylation patterns appear compared to their chronological age. The finding was consistent: people with CHIP showed higher EAA than those without it.
Larger clones, older-looking DNA
The association was also dose-dependent. Larger clones of mutated cells correlated with greater biological age acceleration. Across three cross-sectional studies pooled in the meta-analysis, CHIP carriers appeared 1.2 to 2.8 years older on established epigenetic clocks, including the Horvath and GrimAge clocks.
Two gene mutations stood out: DNMT3A and TET2. Both are involved in regulating DNA methylation. Mutations in TET2 were associated with stronger epigenetic aging signals than mutations in DNMT3A. This suggests that not all CHIP cases carry equal biological weight, and that the mutation type may matter for risk assessment.
What this means going forward
This is a systematic review and meta-analysis, not a causal experiment. The researchers themselves note that larger longitudinal studies are needed to determine whether CHIP actively drives epigenetic aging or merely correlates with it. It also remains unclear whether EAA adds prognostic value for morbidity and mortality beyond what CHIP status alone already predicts.
Still, the finding raises an intriguing possibility: epigenetic clocks may capture something that standard blood tests miss. If CHIP and EAA together define a sharper risk profile than either alone, this combination could become clinically useful for identifying people at elevated risk of cardiovascular and other age-related conditions. The study appeared in Ageing Research Reviews.
Search terms to explore further: clonal hematopoiesis aging | epigenetic age acceleration | DNA methylation clock